Systemy dostarczania leków - przełom w terapii nowotworów z użyciem antracyklin

• Autorzy: Szyszko K. , Pawlowski K. M. , Majchrzak K. , Mucha J. , Motyl T. , Krol M.

Warianty tytułu

EN

Drug delivery systems: Breakthroughs in cancer therapy with anthracyclines

• Języki publikacji: PL

Abstrakty

EN

Anthracyclines have commonly been used in the treatment of many cancers in humans and animals for more than two decades. Unfortunately, the cardiotoxicity of these drugs and a mechanism of chemoresistance to anthracyclines are the main factors limiting their use. Drug delivery systems (DDS) are of great promise in cancer therapy because they transport anthracyclines to cancer cells via endocytosis. Drugs transported with delivery systems are also less toxic. The best-studied drug carriers are liposomes, micelles, dendrimers, as well as polymeric and viral nanoparticles. They increase the apoptosis/necrosis of cancer cells, but the drugs are less toxic to normal cells and tissues. Modern drug delivery systems can improve anticancer therapy in humans and in animals.

Słowa kluczowe

PL

nowotwory; leczenie; terapia przeciwnowotworowa; antracykliny; podawanie lekow; systemy dostarczania lekow; nosniki lekow; liposomy; micele; dendrymery; nanoczasteczki; nanoczasteczki wirusowe

• Wydawca: -
• Czasopismo: Medycyna Weterynaryjna
• Rocznik: 2012
• Tom: 68
• Numer: 05
• Opis fizyczny: s.269-273,rys.,bibliogr.

Twórcy

autor

Szyszko K.

• Katedra Nauk Fizjologicznych, Wydział Medycyny Weterynaryjnej, Szkoła Główna Gospodarstwa Wiejskiego, ul.Nowoursynowska 159, 02-787 Warszawa

autor

Pawlowski K. M.

autor

Majchrzak K.

autor

Mucha J.

autor

Motyl T.

autor

Krol M.

Bibliografia

• 1.Arai M., Tomaru K., Takizawa T., Sekiguchi K., Yokoyama T., Suzuki T., Nagai R.: Sarcoplasmic reticulum genes are selectively down-regulated in cardiomyopathy produced by doxorubicin in rabbits. J. Mol. Cell Cardiol. 1998, 30, 243-254.
• 2.Bangham A. D.: Lipid bilayers and biomembranes. Annu. Rev. Biochem. 1972, 41, 753-776.
• 3.Batrakova E. V., Dorodnych T. Y., Klinskii E. Y., Kliushnenkova E. N., Shemchukova O. B., Goncharova O. N., Arjakov S. A., Alakhov V. Y., Kabanov A. V.: Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br. J. Cancer 1996, 74, 1545-1552.
• 4.Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., Lerebours F., Beuzard Y., Janin A., de The H.: Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet 2002, 360, 852-854.
• 5.Cho K., Wang Xu, Nie Sh, Chen Z., Shin D. M.: Therapeutic Nanoparticles for Drug Delivery in Cancer. Clin. Cancer Res. 2008, 14, 1310-1316.
• 6.Clementi M. E., Giardina B., Di Stasio E., Mordente A., Misiti F.: Doxorubicin-derived metabolites induce release of cytochrome C and inhibition of respiration on cardiac isolated mitochondria. Anticancer Res. 2003, 23, 2445-2450.
• 7.Denmeade S. R., Nagy A., Gao J., Lilja H., Schally A. V., Isaacs J. T.: Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res. 1998, 58, 2537-2540.
• 8.Drummond D. C., Meyer O., Hong K., Kirpotin D. B., Papahadjopoulos D.: Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999, 51, 691-743.
• 9.Duncan R.: The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. 2003, 2, 347-360.
• 10.Duncan R., Vicent M. J., Greco F., Nicholson R. I.: Polymer-drug conjugates: towards a novel approach for the treatment of endrocine-related cancer. Endocr. Relat. Cancer 2005, 12, 189-199.
• 11.Gabizon A., Papahadjopoulos D.: Liposome formulations with prolonged circulation time in blood andenhanced uptake by tumors. Proc. natl. Acad. Sci. USA 1988, 85, 6949-6953.
• 12.Gabizon A., Shmeeda H., Horowitz A. T., Zalipsky S.: Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. 2004, 56, 1177-1192.
• 13.Gariboldi M. B., Ravizza R., Riganti L., Meschini S., Calcabrini A., Marra M., Arancia G., Dolfini E., Monti E.: Molecular determinants of intrinsic resistance to doxorubicin in human cancer cell lines. Int. J. Oncol. 2003, 22, 1057-1064.
• 14.Gennes P. G.: A second type of phase separation in polymer solutions. C.R. Acad. Sci. 1991, 313-II, 1117-1122.
• 15.Gniazdowski M., Denny W. A., Nelson S. M., Czyz M.: Transcription factors as targets for DNA-interacting drugs. Curr. Med. Chem. 2003, 10, 909-924.
• 16.Gradishar W. J., Tjulandin S., Davidson N.: Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2005, 23, 7794-7803.
• 17.Green M. R., Manikhas G. M., Orlov S.: Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced nonsmall-cell lung cancer. Ann. Oncol. 2006, 17, 1263-1268.
• 18.Haag R., Kratz F.: Polymer therapeutics: concepts and applications. Angew. Chem. Int. Ed. Engl. 2006, 45, 1198-1215.
• 19.Hale J. P., Lewis I. J.: Anthracyclines: cardiotoxicity and its prevention. Arch. Dis. Childhood 1994, 71, 457-462.
• 20.Han H. D, Lee A., Song C. K., Hwang T., Seong H., Lee C. O., Shin B. C.: In vivo distribution and antitumor activity of heparin-stabilized doxorubicin-loaded liposomes. Int. J. Pharm. 2006, 313, 181-188.
• 21.Herman E. H., Rahman A., Ferrans A. V., Vick J. A.,. Schein P. S.: Prevention of Chronic Doxorubicin Cardiotoxicity in Beagles by Liposomal Encapsulation. Cancer Res. 1983, 43, 5427-5432.
• 22.Hovorka O., Etrych T., Subr V., Strohalm J., Ulbrich K., Rihova B.: HPMA based macromolecular therapeutics: internalization, intracellular pathway and cell death depend on the character of covalent bond between the drug and the peptidic spacer and alsoon spacer composition. J. Drug Target. 2006, 14, 391-403.
• 23.Iliskovic N., Singal P. K.: Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am. J. Pathol. 1997, 150, 727-734.
• 24.Jang S. H., Wientjes M. G., Lu D., Au J. L.: Drug delivery and transport to solid tumors. Pharm. Res. 2003, 20, 1337-1350.
• 25.Kang Y. J., Zhou Z. X., Wang G. W., Buridi A., Klein J. B.: Suppression by metallothionein of doxorubicin-induced cardiomyocyte apoptosis through inhibition of p38 mitogen-activated protein kinases. J. Biol. Chem. 2000, 275, 13690-13698.
• 26.Kania B. F.: Praktyczna chemioterapia weterynaryjna. MEDYK sp. z o.o. Warszawa 2005, wyd. II poprawione, 401-403.
• 27.Kataoka K., Harada A.: Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47, 113-131.
• 28.Kik K., Lwow F., Szmigiero L.: Polimerowe i oligomerowe nośniki doksorubicyny. Polymers in Medicine 2007, 37, 1-25.
• 29.Kim T. Y., Kim D. W., Chung J. Y.: Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin. Cancer Res. 2004, 10, 3708-3716.
• 30.Król M., Pawłowski K. M., Majchrzak K., Szyszko K., Motyl T.: Why chemotherapy can fail? Review. Pol. J. Vet. Sci. 2010, 13, 399-406.
• 31.Lee C. C., MacKay J. A.: Designing dendrimers for biological applications. Nature Biotechnology 2005, 23, 1517-1526.
• 32.Maeda H., Wu J., Sawa T., Matsumura Y., Hori K.: Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control Release 2000, 65, 271-284.
• 33.Markman M.: Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary. Expert Opin. Pharmacother. 2006, 7, 1469-1474.
• 34.Matsumura Y., Hamaguchi T., Ura T., Muro K., Yamada Y., ShimadaY., Shirao K., Okusaka T., Ueno H., Ikeda M., Watanabe N.: Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle encapsulated, doxorubicin. Br. J. Cancer 2004, 91, 1775-1781.
• 35.Monneret C.: Recent developments in the field of antitumour anthracyclines. Eur. J. Med. Chem. 2001, 36, 483-493.
• 36.Morris J., Dobson J.: Onkologia małych zwierząt. SIMA WLW Warszawa 2003, 50-276.
• 37.Nabholtz J. M., Falkson C., Campos D., Szanto J., Martin M., Chan S., Pienkowski T., Zaluski J., Pinter T., Krzakowski M., Vorobiof D., Leonard R., Kennedy I., Azli N., Murawsky M., Riva A., Pouillart P.: TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J. Clin. Oncol. 2003, 21, 968-975.
• 38.Nevozhay D., Kańska U., Budzyńska R., Boratyński J.: Współczesny stan badań nad koniugatami i innymi systemami dostarczania leków w leczeniu schorzeń nowotworowych i innych jednostek chorobowych. Post. Hig. Med. Dośw. 2007, 61, 350-360.
• 39.Olson R. D., Li X., Palade P., Shadle S. E., Mushlin P. S., Gambliel H. A., Fill M., Boucek R. J. Jr, Cusack B. J.: Sarcoplasmic reticulum calcium release is stimulated and inhibited by daunorubicin and daunorubicinol. Toxicol. Appl. Pharmacol. 2000, 169, 168-176.
• 40.Penault-Llorca F., Cayre A., Bouchet Mishellany F., Amat S., Feillel V., Le Bouedec G., Ferriere J. P., De Latour M., Chollet P.: Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int. J. Oncol. 2003, 22, 1319-1325.
• 41.Rivera E.: Current status of liposomal anthracycline therapy in metastatic breast cancer. Clin. Breast Cancer 2003, 4, 76-83.
• 42.Rosenthal E., Poizot-Martin I., Saint-Marc T., Spano J. P., Cacoub P.: GroupDNXS. Phase IV study of liposomal daunorubicin (DaunoXome) in AIDS-related Kaposi sarcoma. Am. Clin. Oncol. 2002, 25, 57-59.
• 43.Safra T., Muggia F., Jeffers S., Tsao-Wei D. D., Groshen S., Lyass O., Henderson R., Berry G., Gabizon A.: Pegylated liposomal doxorubicin (Doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann. Oncol. 2000, 11, 1029-1033.
• 44.Seymour L. W., Ferry D. R., Anderson D., Hesslewood S., Julypan P. J., Poyner R., Doran J., Young A. M., Burtles S., Kerr D. J.: Cancer Research Campaign Phase I/II Clinical Trials committee. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. J. Clin. Oncol. 2002, 20, 1668-1676.
• 45.Singh P., Destito G., Schneemann A., Manchester M.: Canine parvovirus-like particles, a novel nanomaterial for tumor targeting. J. Nanobiotechnol. 2006, 13, 4:2.
• 46.Steinherz L. J., Steinherz P. G., Tan C. T., Heller G., Murphy M. L.: Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991, 266, 1672-1677.
• 47.Szuławska A., Czyż M.: Molekularne mechanizmy działania antracyklin. Postepy Hig. Med. Dośw. 2006, 60, 78-100.
• 48.Szyszko K., Pawłowski K. M., Motyl T., Król M.: Chemoresistance in cancer: not only a human problem. Med. Weter. 2011, 67, 453-457.
• 49.Takakura Y., Hashida M.: Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 1996, 13, 820-831.
• 50.Tokarska-Schlattner M., Wallimann T., Schlattner U.: Multiple interference of anthracyclines with mitochondrial creatine kinases: preferential damage of the cardiac isoenzyme and its implications for drug cardiotoxicity. Mol. Pharmacol. 2002, 61, 516-523.
• 51.Umalkar D. G., Rajesh K. S., Bangale G. S., Rathinaraj B. S., Shinde G. V., Panicker P. S.: Applications of liposomes in medicine - a review. Pharm Sci. Monit. 2011, 2, 24-39.
• 52.Woodle M. C., Lasic D. D.: Sterically stabilized vesicles. Biochim. Biophys. Acta 1992, 1113, 171-199.
• 53.Yamaoka M., Yamaguchi S., Suzuki T., Okuyama M., Nitobe J., Nakamura N., Mitsui Y., Tomoike H.: Apoptosis in rat cardiac myocytes induced by Fas ligand: priming for Fas-mediated apoptosis with doxorubicin. J. Mol. Cell Cardiol. 2000, 32, 881-889.
• 54.Zucchi R., Danesi R.: Cardiac toxicity of antineoplastic anthracyclines. Curr. Med. Chem. Anticancer Agents 2003, 3, 151-171.